Search clinical trials for: Pegylated interferon alpha 2b

Total 899 results

Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC; Novartis; Uppsala University Hospital

Terminated

Nilotinib Plus Pegylated Interferon-α2b in CML

Chronic Myeloid Leukemia

Netherlands, Denmark, Sweden, Finland, Norway
Biolex Therapeutics, Inc.

Completed

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C (PLUS)

Hepatitis C

United States
Emory University
CURE Childhood Cancer, Inc.

Completed

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Juvenile Pilocytic Astrocytomas | Optic Pathway Gliomas

United States
HepNet Study House, German Liverfoundation
Hannover Medical School

Terminated

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients (OPTEX2/3)

Hepatitis C, Chronic

Germany
The Wistar Institute
University of Pennsylvania; Merck Sharp & Dohme LLC

Completed

Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV

HIV-1 Infection

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Essential Thrombocytopenia

China
Merck Sharp & Dohme LLC

Completed

PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

Hepatitis B, Chronic
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy

HIV Infection

United States
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia

Essential Thrombocytopenia

China
Merck Sharp & Dohme LLC

Terminated

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Chronic Myelogenous Leukemia
Merck Sharp & Dohme LLC

Completed

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

Melanoma
Ochsner Health System
NewLink Genetics Corporation

Unknown

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

Melanoma

United States
St. Jude Children's Research Hospital
Schering-Plough

Active, not recruiting

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Malignant Melanoma

United States
Clinical Research Organization, Dhaka, Bangladesh

Unknown

NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients (NASVAC)

Chronic Hepatitis B

Bangladesh
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Hepatitis B, Chronic
Anhui Medical University
First Affiliated Hospital Bengbu Medical College; The Second Hospital of Anhui... and other collaborators

Recruiting

Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B (EPCP)

Hepatitis B, Chronic

China
Emory University
Bayer

Completed

Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

Leukemia

United States
M.D. Anderson Cancer Center
Schering-Plough; Eisai Inc.

Terminated

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Melanoma

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Hepatitis C, Chronic
Ullevaal University Hospital
Schering-Plough

Completed

14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

Hepatitis C Virus Infection

Norway
Thomas Stauffer Larsen

Completed

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

Denmark
H. Lee Moffitt Cancer Center and Research Institute

Completed

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Carcinoma, Squamous Cell | Squamous Cell Carcinoma of Skin

United States
Bausch Health Americas, Inc.

Completed

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive

Chronic Hepatitis C
Kyushu University

Unknown

PEG-IFN Plus Ribavirin Combination Therapy for Older Patients

Hepatitis C Virus

Japan
Amr Hafez
Ain Shams University

Completed

Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)

Hepatitis C | Hepatitis C, Chronic
Columbia University
Merck Sharp & Dohme LLC

Withdrawn

Boceprevir in End Stage Renal Disease (ESRD)

End Stage Renal Disease | Hepatitis C Infection
Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland
Northwestern University
National Cancer Institute (NCI)

Terminated

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL

Lymphoma

United States
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Withdrawn

Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)

Liver Cirrhosis | HIV Infections | Hepatitis C
Merck Sharp & Dohme LLC

Completed

Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC
Bioikos Ambiente Srl

Completed

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

Hepatitis C
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
Luis Montaner
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Unknown

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) (BEAT-2)

HIV/AIDS | HIV | HIV-1 Infection

United States
M.D. Anderson Cancer Center
Schering-Plough

Completed

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Melanoma

United States
AOP Orphan Pharmaceuticals AG
PharmaEssentia Corporation (Co-Sponsor for USA)

Completed

Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients (PEN-PV)

Polycythemia Vera

Austria, Bulgaria, Czech Republic, France, Hungary, Poland, Slovakia, Ukraine
Seoul National University Hospital
Roche Pharma AG; SciClone Pharmaceuticals

Completed

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

HIV Infections | Hepatitis C | HCV Infection
Institute of Hematology & Blood Diseases Hospital

Recruiting

Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV (PV)

Polycythemia Vera

China
Australasian Leukaemia and Lymphoma Group
Merck Sharp & Dohme LLC; Novartis Pharmaceuticals

Unknown

Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (PInNACLe)

Chronic Myeloid Leukaemia

Australia
Merck Sharp & Dohme LLC

Completed

Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

Hepatitis C, Chronic
Philipps University Marburg Medical Center
Deutsche Krebshilfe e.V., Bonn (Germany); AOP Orphan Pharmaceuticals AG

Completed

ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission (ENDURE-CML-IX)

Chronic Myeloid Leukemia in Remission

France, Germany
AOP Orphan Pharmaceuticals AG
PharmaEssentia Corporation (for the U.S.)

Completed

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)

Polycythemia Vera

Spain, Austria, Bulgaria, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine, Czechia
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Region Skane

Completed

Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy

Hepatitis C

Sweden
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Suspended

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Peking University People's Hospital

Unknown

Interferon α for the Therapy of Minimal Residual Disease

Leukemia

China
Peking University People's Hospital

Unknown

Interferon-α After DLI for the Prevention of Relapse (IDPR-HSCT)

Leukemia

China
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

HIV Infections | Hepatitis C

United States, Puerto Rico

3

Subscribe